Paper79613
Macrophage-lymphocyte interaction in migration inhibition factor (MIF) production against soluble or cellular tumor-associated antigens. I. Characteristics and genetic control of two different mechanisms of stimulating MIF production.
Landolfo S and 2 others. J Immunol, 1978. Cited by 37 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Macrophage-lymphocyte interaction in migration inhibition factor (MIF) production against soluble or cellular tumor-associated antigens. I. Characteristics and genetic control of two different mechanisms of stimulating MIF production. Papers, record 79613. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/79613
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Macrophage-lymphocyte interaction in migration inhibition factor (MIF) production against soluble or cellular tumor-associated antigens. I. Characteristics and genetic control of two different mechanisms of stimulating MIF production.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, Neoplasm | Major topic |
| Immunity, Cellular | Major topic |
| Lymphocytes | Major topic |
| Macrophage Migration-Inhibitory Factors | Major topic |
| Macrophages | Major topic |
| Animals | |
| Epitopes | |
| Fibroblasts | |
| Lymphocyte Cooperation | |
| Mercaptoethanol | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Inbred C57BL | |
| Mice, Inbred DBA | |
| Sarcoma, Experimental | |
| Solubility | |
| Spleen |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 6,974,678 | HLA-B8 and cell-mediated immunity to gluten. | Gut | 1981 | https://conductscience.org/library/papers/6974678 | PubMed |
| 6,563,944 | Enhancement of natural killer cell activity in mice by treatment with a thymic factor. | Cancer Immunol Immunother | 1984 | https://conductscience.org/library/papers/6563944 | PubMed |
| 6,395,409 | The role of lymphokines in delayed-type hypersensitivity reactions. | Springer Semin Immunopathol | 1984 | https://conductscience.org/library/papers/6395409 | PubMed |
| 6,352,489 | Natural cell-mediated cytotoxicity against Candida albicans induced by cyclophosphamide: nature of the in vitro cytotoxic effector. | Infect Immun | 1983 | https://conductscience.org/library/papers/6352489 | PubMed |
| 3,943,907 | Evidence for macrophage-mediated protection against lethal Candida albicans infection. | Infect Immun | 1986 | https://conductscience.org/library/papers/3943907 | PubMed |
| 3,899,934 | Induction of natural killer cell activity by inactivated Candida albicans in mice. | Infect Immun | 1985 | https://conductscience.org/library/papers/3899934 | PubMed |
| 389,784 | Interaction of subpopulations of murine lymph node lymphocytes in antigen-induced [14C]-thymidine incorporation: T and B cell synergy in the response to antigen. | Immunology | 1979 | https://conductscience.org/library/papers/389784 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MIF | 4,282 | PubTator's text mining | https://conductscience.org/library/genes/4282 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/79613
GET https://conductscience.org/api/papers/v1/79613/authors